Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HPGD Overexpression Attenuates Tumorigenesis and EMT in Clear Cell Renal Cell Carcinoma by Upregulating SLCO2A1

NCT06778538 is registered in ClinicalTrials.gov with Shang Panfeng as lead sponsor.

NCT NCT06778538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06778538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HPGD Overexpression Attenuates Tumorigenesis and EMT in Clear Cell Renal Cell Carcinoma by Upregulating SLCO2A1
Lead sponsor
Shang Panfeng
Phase
Observational
Overall status
Completed
Start date
July 1, 2024
Completion date
November 20, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma (ccrcc)